Technical Research on Equities: Zoetis, Actavis, Avanir Pharma, and Salix Pharma

  Technical Research on Equities: Zoetis, Actavis, Avanir Pharma, and Salix
                                    Pharma

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, December 16, 2013

LONDON, December 16, 2013 /PRNewswire/ --

On Friday, December 13, 2013, the U.S. equity market finished on a mixed note.
The S&P 500 ended the day at 1,775.32, down 0.01%; the Dow Jones Industrial
Average closed at 15,755.36, up 0.10%; and the NASDAQ Composite finished at
4,000.98, up 0.06%. The S&P 500 Health Care Sector Index edged 0.04% higher to
close the session at 621.05; and the S&P 500 Pharmaceuticals Sub Industry
Index closed at 477.87, up 0.13%. The S&P 500 Pharmaceuticals Sub Industry
Index has gained 4.98% in the previous three months, outperforming the S&P
500, which has gained 4.58% during the same period. The major movers in the
industry included Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), AVANIR
Pharmaceuticals Inc. (NASDAQ: AVNR), and Salix Pharmaceuticals Ltd (NASDAQ:
SLXP). All these companies are tracked by AAAResearchReports.com. Free
technical research on ZTS, ACT, AVNR, and SLXP can be downloaded upon signing
up at:

http://www.aaaresearchreports.com/register/ 

Zoetis Inc.'s stock finished the day 1.32% higher at $31.58 on Friday, after
oscillating between $31.23 and $31.89 during the trading session. A total of
3.29 million shares were traded, which is below the daily average volume of
3.82 million. The company's shares have gained 0.70% in previous three trading
sessions, outperforming the S&P 500, which has lost 1.51% during the same
period. However, Zoetis Inc.'s stock is trading below its 50-day and 200-day
moving averages of $31.80 and $31.78, respectively. Sign up and read the
complimentary report on ZTS at:

http://www.AAAResearchReports.com/ZTS121613.pdf

On Friday, Actavis PLC's stock closed the day at $159.82, up 0.28% from the
previous day's closing price of $159.38. The company's shares vacillated
between $158.92 and $161.36 during the trading session. A total of 0.89
million shares were traded, which is below the daily average volume of 1.49
million. The company's shares have surged 17.87% in the previous three months,
compared to a gain of 4.58% in the S&P 500 during the same period. Moreover,
Actavis plc's stock is trading above its 50-day and 200-day moving averages of
$155.23 and $128.36, respectively. The free report on ACT can be downloaded by
signing up now at:

http://www.AAAResearchReports.com/ACT121613.pdf

Shares in AVANIR Pharmaceuticals Inc. plummeted on Friday, ending the day
10.00% lower at$2.84, after fluctuating between$2.83 and $3.18 during the
trading session. A total of 7.43 million shares were traded, which is above
the daily average volume of 2.68 million. The company's shares have lost
30.51% in the previous three months, underperforming the S&P 500, which has
gained 4.58% during the same period. Furthermore, AVANIR Pharmaceuticals
Inc.'s stock is trading below its 50-day and 200-day moving averages of $4.33
and $4.04, respectively. A free report on AVNR can be accessed by registering
at:

http://www.AAAResearchReports.com/AVNR121613.pdf

Salix Pharmaceuticals Ltd's stock edged higher on Friday, even as the broader
market finished on a mixed note. The company's shares closed the day at
$84.05, up 0.21%, after oscillating between $83.44 and $84.56 during the
trading session. A total of 0.64 million shares were traded, which is below
the daily average volume of 0.83 million. The company's shares have surged
25.22% in the previous three months, outperforming the S&P 500, which has
advanced 4.58% during the same period. Further, Salix Pharmaceuticals Ltd's
stock is trading above its 50-day and 200-day moving averages of $78.55 and
$65.79, respectively. Register with AAA Research Reports and download research
on SLXP for free at:

http://www.AAAResearchReports.com/SLXP121613.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE AAA Research Reports

Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
info@aaaresearchreports.com
 
Press spacebar to pause and continue. Press esc to stop.